- Report
- April 2024
- 183 Pages
Global
From €4710EUR$4,900USD£4,039GBP
- Report
- January 2024
- 200 Pages
Global
From €3989EUR$4,150USD£3,421GBP
- Report
- January 2023
- 315 Pages
Global
From €4613EUR$4,799USD£3,955GBP
- Report
- November 2021
- 261 Pages
Global
From €5046EUR$5,250USD£4,327GBP
- Report
- May 2021
- 208 Pages
Global
From €4758EUR$4,950USD£4,080GBP
- Report
- November 2018
- 258 Pages
Global
From €7684EUR$7,995USD£6,590GBP
- Report
- July 2022
- 176 Pages
Global
From €5545EUR$5,769USD£4,755GBP
- Book
- April 2020
- 272 Pages
- Book
- August 2021
- 312 Pages
- Book
- February 2024
- 640 Pages
- Book
- September 2023
- 288 Pages
- Book
- September 2023
- 288 Pages
- Book
- April 2019
- 816 Pages
- Book
- July 2018
- 832 Pages
- Book
- October 2015
- 520 Pages
- Book
- March 2015
- 352 Pages
- Book
- October 2013
- 624 Pages
- Book
- February 2012
- 496 Pages
Hepatocellular Carcinoma (HCC) is a type of cancer that originates in the liver. It is the most common form of liver cancer and is the third leading cause of cancer-related deaths worldwide. HCC is typically diagnosed in individuals with underlying liver diseases such as cirrhosis, hepatitis B or C, and non-alcoholic fatty liver disease. Treatment options for HCC include surgery, radiation therapy, chemotherapy, and targeted therapy.
The oncology market for HCC is highly competitive, with a number of companies offering treatments and therapies. These include AbbVie, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Roche, and Takeda. Additionally, there are a number of smaller companies that are developing novel therapies for HCC, such as Aduro Biotech, ArQule, and Oncoceutics. Show Less Read more